Carbon-Ion Radiation Therapy for Unresectable Locally Recurrent Colorectal Cancer: A Promising Curative Treatment for Both Radiation Therapy: Naïve Cases and Reirradiation Cases

被引:2
|
作者
Takiyama, Hirotoshi [1 ]
Yamada, Shigeru [1 ]
Isozaki, Tetsuro [1 ]
Ikawa, Hiroaki [1 ]
Shinoto, Makoto [1 ]
Imai, Reiko [1 ]
Koto, Masashi [1 ]
机构
[1] QST Hosp, Natl Inst Quantum Sci & Technol, Chiba, Japan
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 03期
关键词
RECTAL-CANCER; RADIOTHERAPY; SURGERY;
D O I
10.1016/j.ijrobp.2023.09.036
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: It is difficult to effectively cure patients with unresectable locally recurrent colorectal cancers (LRCRCs) using conventional chemotherapy or chemoradiation therapy. Furthermore, treatment options vary depending on the patient's history of radiation therapy. Carbon-ion radiation therapy (CIRT) is a potentially curative treatment for these patients. Here, we compare the treatment outcomes of radiation therapy-naive cases (nRT) and re-irradiation cases (reRT). Methods and Materials: Patients with LRCRC treated with CIRT at QST Hospital between 2003 and 2019 were eligible. CIRT was administered daily 4 d/wk for 16 fractions. The total irradiated dose was set at 73.6 Gy (relative biologic effectiveness-weighted dose [RBE]) for nRT and 70.4 Gy (RBE) for reRT patients. Results: We included 390 nRT cases and 83 reRT cases. The median follow-up period from the initiation of CIRT was 48 (5208) months. The 3-year overall survival (OS) rates for nRT and reRT were 73% (95% CI, 68%-77%) and 76% (65%-84%), respectively. The 5-year OS rates were 50% (45%-55%) and 50% (38%-61%), respectively. These rates did not differ signifi- cantly (P = .55). The 3-year local control (LC) rates for nRT (73.6 Gy) and reRT (70.4 Gy) cases were 80% (75%-84%) and 80% (68%-88%), respectively. The 5-year LC rates were 72% (67%-78%) and 69% (55%-81%), respectively, without a signifi- cant difference (P = .56). Conclusions: Our results suggest that CIRT for LRCRC is a very effective and promising treatment for both nRT and reRT cases. O 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:734 / 742
页数:9
相关论文
共 37 条
  • [31] Significant Effect of Carbon-Ion Radiation Therapy Combined With Androgen Deprivation on Biochemical Recurrence Rates in High-Risk Prostate Cancer Patients: A Two-Center Controlled Trial Compare With X-Ray External Beam Radiation Therapy
    Zhao, Xue
    Sakamoto, Shinichi
    Ishikawa, Hitoshi
    Yamada, Yasutaka
    Aoki, Shuri
    Nakajima, Mio
    Sato, Kodai
    Kobayashi, Kana
    Saito, Shinpei
    Wakatsuki, Masaru
    Ichikawa, Tomohiko
    PROSTATE, 2025, 85 (03) : 232 - 242
  • [32] Analysis of the prognostic factors of simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT) in 220 cases of locally advanced squamous esophageal cancer: a retrospective cohort study
    Zhou, Shixiang
    Yang, Yan
    Zhang, Qun
    Zhu, Chaomang
    Cai, Peng
    Li, Duojie
    ANNALS OF TRANSLATIONAL MEDICINE, 2023,
  • [33] Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome
    Jiang, Ping
    van der Horst, Christof
    Kimmig, Bernhard
    Zinsser, Fabian
    Poppe, Bjoern
    Luetzen, Ulf
    Juenemann, Klaus-Peter
    Dunst, Juergen
    Siebert, Frank-Andre
    BRACHYTHERAPY, 2017, 16 (01) : 186 - 192
  • [34] A Study of 358 Cases of Locally Advanced Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiation Therapy: Improving the Seventh Edition of the American Joint Committee on Cancer T-Staging System
    Zhou, Qin
    He, Yuxiang
    Zhao, Yajie
    Wang, Yin
    Kuang, Weilu
    Shen, Liangfang
    BIOMED RESEARCH INTERNATIONAL, 2017, 2017
  • [35] Combination of radiation therapy for brain metastasis and anti-PD-1/PD-L1 treatment in non-small cell lung cancer: two cases and review of the literature
    Nigro, Olga
    Tuzi, Alessandro
    Coppola, Andrea
    Tartaro, Tiziana
    Chini, Claudio
    Pinotti, Graziella
    ANTI-CANCER DRUGS, 2021, 32 (04) : 460 - 464
  • [36] Treatment outcomes of patients with stage III non-small cell lung cancer and interstitial lung diseases receiving intensity-modulated radiation therapy: A single-center experience of 85 cases
    Wu, Linfang
    Zhao, Shijun
    Huang, Hui
    Wang, Wenqing
    Zhang, Tao
    Zhou, Zongmei
    Feng, Qinfu
    Liang, Jun
    Xiao, Zefen
    Hui, Zhouguang
    Lv, Jima
    Bi, Nan
    Wang, Luhua
    THORACIC CANCER, 2022, 13 (11) : 1583 - 1591
  • [37] Non-surgical care for locally advanced breast cancer: Radiologically assessed therapeutic outcome of a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II) with systemic chemotherapy
    Miyatake, Kana
    Kubota, Kei
    Ogawa, Yasuhiro
    Hamada, Norihiko
    Murata, Yoriko
    Nishioka, Akihito
    ONCOLOGY REPORTS, 2010, 24 (05) : 1161 - 1168